TNFSF11 and retinal disorder: Treatment with RANKL monoclonal antibodies (denosumab) is currently expanding, as it shows good results on the reduction of ALP, bone pain, and deformities; however, no clear influence on retinopathy or hearing loss in adults has been observed and its safe use on children has yet to be verified [1].